Literature DB >> 32749848

Knockdown of microRNA-103a-3p inhibits the malignancy of thyroid cancer cells through Hippo signaling pathway by upregulating LATS1.

M L Zhang1, W H Sun1, H Q Wu1, Z D Liu1, P Wang1.   

Abstract

MicroRNA (miR)-103a-3p has been shown to be involved in the development and progression of several types of cancer. However, the role of miR-103a-3p in thyroid cancer remains unclear. This study investigated the effects of miR-103a-3p on the biological characteristics of thyroid cancer cells and related mechanisms. In the present study, we found that the expression of miR-103a-3p was increased in thyroid cancer tissues compared to that in non-cancerous tissues. Additionally, the expression of miR-103a-3p in thyroid cancer cell lines (TPC-1, SW579, BHT101, K1) was markedly higher than that in the human thyroid cell line (Nthy-ori3-1). Silencing of miR-103a-3p obviously inhibited proliferation, migration, and invasion and promoted apoptosis of BHT101 cells. miR-103a-3p upregulation promoted the proliferation, migration, and invasion and inhibited apoptosis of K1 cells. Mechanistically, LATS1 was identified as a functional target of miR-103a-3p, and miR-103a-3p negatively regulated LATS1 expression. miR-103a-3p knockdown (or upregulation) partially reversed the effects of LATS1 knockdown (or overexpression) on proliferation, apoptosis, migration, and invasion of thyroid cancer cells. LATS1 knockdown inhibited the phosphorylation of YAP in BHT101 cells and promoted the nuclear translocation of YAP. Whereas, miR-103a-3p downregulation reversed the inhibitory effect of LATS1 knockdown on the Hippo signaling pathway. Moreover, overexpression of LATS1 induced YAP phosphorylation in K1 cells and inhibits nuclear translocation of YAP, and the upregulation of miR-103a-3p reversed this effect. The knockdown of miR-103a-3p inhibited tumor growth and progression in vivo. Taken together, knockdown of miR-103a-3p inhibits proliferation, migration, and invasion and promotes apoptosis of thyroid cancer cells through the Hippo signaling pathway by upregulating LATS1.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32749848     DOI: 10.4149/neo_2020_191224N1331

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  MiR-103a-3p Contributes to the Progression of Colorectal Cancer by Regulating GREM2 Expression.

Authors:  Zongxiang Zhang; Xiaolian Zhu
Journal:  Yonsei Med J       Date:  2022-06       Impact factor: 3.052

2.  lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR‑424‑5p/LATS1 axis.

Authors:  Xuemei Han; Yuxi Jia; Xiangru Chen; Chengkuan Sun; Jing Sun
Journal:  Oncol Rep       Date:  2021-09-20       Impact factor: 3.906

3.  Circulating microRNA-103a-3p could be a diagnostic and prognostic biomarker for breast cancer.

Authors:  Hui Liu; Qing-Zhao Bian; Wei Zhang; Hai-Bin Cui
Journal:  Oncol Lett       Date:  2021-12-03       Impact factor: 2.967

4.  LMO3 promotes proliferation and metastasis of papillary thyroid carcinoma cells by regulating LIMK1-mediated cofilin and the β-catenin pathway.

Authors:  Zeyi Ling; Xiaoli Long; Ying Wu; Jie Li; Mingliang Feng
Journal:  Open Med (Wars)       Date:  2022-03-07

5.  The promotional effect of microRNA-103a-3p in cervical cancer cells by regulating the ubiquitin ligase FBXW7 function.

Authors:  Li Ren; Jinjin Yang; Xiyan Meng; Junjun Zhang; Yiran Zhang
Journal:  Hum Cell       Date:  2022-01-30       Impact factor: 4.174

6.  Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers.

Authors:  Wei Han; Chun-Tao Shi; Jun Ma; Hua Chen; Qi-Xiang Shao; Xiao-Jiao Gao; Ying Zhou; Jing-Feng Gu; Hao-Nan Wang
Journal:  Heliyon       Date:  2022-09-28

7.  MicroRNA-103a-3p Promotes Cell Proliferation and Invasion in Non-Small-Cell Lung Cancer Cells through Akt Pathway by Targeting PTEN.

Authors:  Haixun Li; Muren Huhe; Jiaxin Lou
Journal:  Biomed Res Int       Date:  2021-07-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.